Hovione LLC (10316445) agreed to license its dry powder inhaler technology, jointly to Sankyo Company Ltd. (TYO: 6417)) and Biota Holdings Ltd. (ASX: BTA) for the delivery of long acting neuraminidase inhibitors (LANI).
The long acting neuraminidase inhibitors (LANI) - owned by Sankyo and Biota – is a novel compound active against influenza virus that is expected to remain active for several days and require to be taken once only.
According to Peter Villax, Hovione Vice-President:
"This agreement is the confirmation that Hovione is recognized as a reliable partner in inhalation product development. We are the only independent company with expertise in every aspect of inhalation, from chemical development to particle design, from device to formulation development."
Outside the field of influenza, Hovione retains all inhaler rights.
Find more details from the press release.
Comment Preview